Compare GSK plc (GSK) vs Johnson Controls International PLC (JCI) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

JCI trades at $139.67, down 3.84% on the day, with a bullish technical signal from moving averages and support at $140. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.32. Revenue for 2025 was $23.60B, net income $3.29B, and profit margin expanded to 13.94%. Analyst consensus is strongly bullish with a $158.29 price target and no sell ratings among 45 analysts. Recent news highlights innovation awards and dividend declarations.

JCI presents a favorable outlook with consistent earnings beats, strong analyst support, and exposure to growth areas like energy efficiency. Risks include high valuation multiples (P/E 43.66) and increasing debt-to-asset ratio (26.06% in 2025). The stock's proximity to the $140 support level offers a potential entry point, but macroeconomic headwinds and execution risks in competitive markets warrant caution for investors seeking stable returns.